RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Armata Pharmaceuticals Market capitalization 2024

Armata Pharmaceuticals Market capitalization

98.13 M USD

Armata Pharmaceuticals Dividend yield

Ticker

ARMP

ISIN

US04216R1023

WKN

A2PKLC

In 2024, Armata Pharmaceuticals's market cap stood at 98.13 M USD, a 84.53% increase from the 53.18 M USD market cap in the previous year.

The Armata Pharmaceuticals Market capitalization history

YEARREVENUE (undefined USD)GROSS MARGIN (%)NET INCOME (undefined USD)
2028e56.27--4.79
2027e6.09--19.91
2026e---31.34
2025e2.81--47.93
2024e4.63--70.24
20234.53--69.05
20225.51--36.92
20214.47--23.16
20200.82--22.18
2019---19.48
2018---12.11
20170.12--12.84
20160.26--24.28
20150.48--10.79
20140.41-21.82
20130.08--65.2
20120.66--1.11
20110.12--3.79
20088.72--20.72
200710.33--16.13
20069.86--33.99
20056.87--19.2
20049.65--14.26
200314.07--14.83
200219.33--23.77

Armata Pharmaceuticals Aktienanalyse

What does Armata Pharmaceuticals do?

Armata Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of therapies for severe bacterial infections. The company was founded in California in 2009 and has been listed on the NASDAQ stock exchange since 2019. The founders of Armata Pharmaceuticals Inc. recognized that antibiotic resistance is a growing problem and that it is crucial to develop new therapies to address the challenges in the fight against bacterial infections. The company's business model is based on the discovery and development of bacteriophage therapies. Bacteriophages are natural viruses that can infect and destroy bacteria. Armata Pharmaceuticals Inc. has two main divisions: Armatavax, which focuses on the development of vaccines against bacterial infections, and Armatamab, which works on the development of monoclonal antibodies that express bacteriophage genes and thus have higher efficacy in combating bacteria. The company is currently developing several products based on bacteriophage therapies. The main product is AR-301, a monoclonal antibody designed to treat Staphylococcus infections causing pneumonia. AR-301 is in phase IIb study and has shown promising results. The company also has several other products in the pipeline, including AR-105 against Pseudomonas aeruginosa infections, AR-201 against Acinetobacter baumannii infections, and AR-401 against Enterobacteriaceae infections. Armata Pharmaceuticals Inc. works closely with various academic institutions and research facilities to explore the potential of bacteriophage therapies and develop new products. The company has acquired a number of patents and intellectual property in this area. To bring its products to market, Armata Pharmaceuticals Inc. has formed strategic partnerships with various companies, including AmpliPhi Biosciences, the United States Department of Defense's Drug Agency (DTRA), and Synthetic Biologics. These partnerships enable the company to lower its development costs while increasing access to a broader market. In summary, Armata Pharmaceuticals Inc. is an innovative biopharmaceutical company specializing in the development of bacteriophage therapies for severe bacterial infections. The company has a strong pipeline of products in various stages of development and is actively working to improve its technology and strengthen its market position. Through its partnerships and commitment to cutting-edge research, Armata Pharmaceuticals Inc. ensures that it is well-positioned to address the challenges in the fight against antibiotic resistance. Armata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Armata Pharmaceuticals's Market Capitalization

Armata Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Armata Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Armata Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Armata Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Armata Pharmaceuticals Stock

What is the current Armata Pharmaceuticals market capitalization?

The current market capitalization of Armata Pharmaceuticals is 98.13 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Armata Pharmaceuticals.

How has the market capitalization of Armata Pharmaceuticals developed in recent years?

The market capitalization of Armata Pharmaceuticals has increased/decreased by 84.53% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Armata Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Armata Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Armata Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Armata Pharmaceuticals pay?

Over the past 12 months, Armata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Armata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Armata Pharmaceuticals?

The current dividend yield of Armata Pharmaceuticals is .

When does Armata Pharmaceuticals pay dividends?

Armata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Armata Pharmaceuticals?

Armata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Armata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Armata Pharmaceuticals located?

Armata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Armata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Armata Pharmaceuticals from 6/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did Armata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/3/2024.

What was the dividend of Armata Pharmaceuticals in the year 2023?

In the year 2023, Armata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Armata Pharmaceuticals pay out the dividend?

The dividends of Armata Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Armata Pharmaceuticals

Our stock analysis for Armata Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Armata Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.